Acute Porphyria Drugs

Monograph

V08CA10 - Gadoxetic Acid
Propably not porphyrinogenic
PNP

Rationale
Gadoxetic disodium is not metabolized by CYP enzymes.
Therapeutic characteristics
Gadoxetic acid is indicated for the detection of focal liver lesions and provides information on the character of lesions in T1-wighted magnetic resonance imaging (MRI). It is for diagnostic use by intravenous administration only. Common side effects are nausea and headache.
Metabolism and pharmacokinetics
Gadoxetate disodium is not metabolized. It is excreted in the urine and feces. Elimination half-life is 1 hour. It is highly water-soluble and less than 10% is bound to proteins in vivo.
Similar drugs
Explore alternative drugs in similar therapeutic classes V08C / V08CA or go back.
References
# Citation details PMID
*Summary of Product Characteristics
1. Norwegian medicines agency. Summary of Product Characteristics (SPC). Primovist.

Tradenames

Primovist Primovist Primovist Primovist Primovist Primovist Gadoxetate disodium ยท Primovist Primovist Primovist Primovist Primovist Primovist Primovist Primovist Primovist Primovist Primovist Acide gadoxetique Acido gadoxetico Gadoxetic acid
In cooperation with IpNet
© NAPOS 2025
An unhandled error has occurred. Reload ๐Ÿ—™